Bone loss induced by cancer treatments in breast and prostate cancer patients

Simple item page
dc.contributor.authorCastañeda, Santos
dc.contributor.authorCasas, Ana
dc.contributor.authorGonzález-Del-Alba, Aránzazu
dc.contributor.authorMartínez-Díaz-Guerra, Guillermo
dc.contributor.authorNogués Solán, Xavier
dc.contributor.authorOjeda Thies, Cristina
dc.contributor.authorTorregrosa Suau, Óscar
dc.contributor.authorRodríguez-Lescure, Álvaro
dc.date.accessioned2022-10-19T06:29:54Z
dc.date.available2022-10-19T06:29:54Z
dc.date.issued2022
dc.description.abstractCancer and cancer therapies are a major factor risk for osteoporosis due to bone loss and deterioration of bone microarchitecture. Both factors contribute to a decrease in bone strength and, consequently, increased bone fragility and risk of fracture. Cancer-associated bone loss is a multifactorial process, and optimal interdisciplinary management of skeletal health, accurate assessment of bone density, and early diagnosis are essential when making decisions aimed at reducing bone loss and fracture risk in patients who have received or are receiving treatment for cancer. In this document, a multidisciplinary group of experts collected the latest evidence on the pathophysiology of osteoporosis and its prevention, diagnosis, and treatment with the support of the Spanish scientific society SEOM. The aim was to provide an up-to-date and in-depth view of osteoporotic risk and its consequences, and to present a series of recommendations aimed at optimizing the management of bone health in the context of cancer.
dc.format.mimetypeapplication/pdf
dc.identifier.citationCastañeda S, Casas A, González-Del-Alba A, Martínez-Díaz-Guerra G, Nogués X, Ojeda Thies C, et al. Bone loss induced by cancer treatments in breast and prostate cancer patients. Clin Transl Oncol. 2022 Nov; 24(11): 2090-2106. DOI: 10.1007/s12094-022-02872-1
dc.identifier.doihttp://dx.doi.org/10.1007/s12094-022-02872-1
dc.identifier.issn1699-048X
dc.identifier.urihttp://hdl.handle.net/10230/54476
dc.language.isoeng
dc.publisherSpringerOpen
dc.rightsCopyright © Castañeda S, Casas A, González-Del-Alba A, Martínez-Díaz-Guerra G, Nogués X, Ojeda Thies C. 2022, corrected publication 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.keywordAntiresorptive agents
dc.subject.keywordBone health
dc.subject.keywordBone turnover marker
dc.subject.keywordCancer
dc.subject.keywordDiagnosis
dc.subject.keywordFragility fracture
dc.subject.keywordHormone deprivation therapy
dc.subject.keywordHormone therapy
dc.subject.keywordOsteoporosis
dc.titleBone loss induced by cancer treatments in breast and prostate cancer patients
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
castaneda-cto-bone.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Download

Collections

License

Rights